Kimberly “Kim” Simmons leads engagements with pharmaceutical companies and payers to uncover the business implications of emerging therapies, delivering actionable insights that shape market access strategies and reduce financial uncertainty. She is responsible for leading clinical drug assessments that inform market adoption assumptions within actuarial forecasting models, with a particular focus on emerging drugs across commercial and government program lines of business. She brings 17+ years of pharmacy experience spanning the pharmaceutical and device industry and the broader pharmacy ecosystem.

Disclaimer: Advisory Board is a subsidiary of Optum. All Advisory Board research, expert perspectives, and recommendations remain independent.